{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:50:46Z","timestamp":1790754646796,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Pathology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.carpath.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,7,24]],"date-time":"2009-07-24T09:12:16Z","timestamp":1248426736000},"page":"293-301","source":"Crossref","is-referenced-by-count":81,"title":["A detailed pathologic examination of heart tissue from three older patients with Anderson\u2013Fabry disease on enzyme replacement therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Mary N.","family":"Sheppard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Florio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kavantzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Close","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaymin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.carpath.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson\u2013Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9499","key":"10.1016\/j.carpath.2009.05.003_bib2","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.carpath.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.carpath.2009.05.003_bib4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.carpath.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.carpath.2009.05.003_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.carpath.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.carpath.2009.05.003_bib8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.carpath.2009.05.003_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson\u2013Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.carpath.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.carpath.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.carpath.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2559.2006.02356.x","article-title":"Spectrum of pathological changes in both ventricles of patients dying suddenly with arrhythmogenic right ventricular dysplasia. Relation of changes to age","volume":"48","author":"Fletcher","year":"2006","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.carpath.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00129784-200202010-00006","article-title":"Apoptosis and heart failure: mechanisms and therapeutic implications","volume":"2","author":"Chen","year":"2002","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10.1016\/j.carpath.2009.05.003_bib14","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"issue":"439","key":"10.1016\/j.carpath.2009.05.003_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1651-2227.2002.tb03105.x","article-title":"Electrocardiographic signs of hypertrophy in Fabry disease-associated hypertrophic cardiomyopathy","volume":"91","author":"Kampmann","year":"2002","journal-title":"Acta Paediatr Suppl"},{"issue":"5","key":"10.1016\/j.carpath.2009.05.003_bib16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0735-1097(86)80238-8","article-title":"Echocardiographic abnormalities and disease severity in Fabry's disease","volume":"7","author":"Goldman","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.carpath.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"23","key":"10.1016\/j.carpath.2009.05.003_bib18","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson\u2013Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.carpath.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJM199704173361603","article-title":"Apoptosis in the failing human heart","volume":"336","author":"Olivetti","year":"1997","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.carpath.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.RES.0000148632.35500.d9","article-title":"The mitochondrial death pathway and cardiac myocyte apoptosis","volume":"95","author":"Crow","year":"2004","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.carpath.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/hh2301.100350","article-title":"Sphingolipid mediators in cardiovascular cell biology and pathology","volume":"89","author":"Levade","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.carpath.2009.05.003_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease. Evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","author":"Barbey","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carpath.2009.05.003_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson\u2013Fabry disease and the effect of treatment with alpha galactosidase A","author":"Elliott","year":"2005","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.carpath.2009.05.003_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0002-9149(94)90106-6","article-title":"Electrophysiologic findings in Fabry's disease with a short PR interval","volume":"74","author":"Pochis","year":"1994","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.carpath.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson\u2013Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.carpath.2009.05.003_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.carpath.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.carpath.2009.05.003_bib28","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.carpath.2009.05.003_bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.carpath.2009.05.003_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.carpath.2009.05.003_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/hrt.2003.023903","article-title":"Improvement of cardiac hypertrophy and ventricular function in a man with Fabry disease by treatment with recombinant alpha-galactosidase A","volume":"90","author":"Komamura","year":"2004","journal-title":"Heart"}],"container-title":["Cardiovascular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880709000477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880709000477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T06:28:16Z","timestamp":1545114496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054880709000477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1054880709000477"],"URL":"https:\/\/doi.org\/10.1016\/j.carpath.2009.05.003","relation":{},"ISSN":["1054-8807"],"issn-type":[{"value":"1054-8807","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}